TIDMIXI

RNS Number : 0424L

IXICO plc

08 September 2021

IXICO plc

("IXICO" or the "Company")

Phase I Multiple System Atrophy contract award worth >$500k

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, announces that it has been awarded a contract by a new biopharmaceutical client to support its Phase I multiple system atrophy clinical trial . Multiple system atrophy (MSA) is a rare condition of the nervous system that causes gradual damage to nerve cells in the brain.

Conducted across investigator sites within the Unites States, the clinical trial will enrol patients with the parkinsonian subtype of MSA (MSA-P) to assess the safety, tolerability, and preliminary efficacy of GDNF gene therapy for this rapidly progressing condition. For the study, IXICO will provide advanced neuroimaging solutions involving structural magnetic resonance imaging (MRI), FDG-PET and DaT scans.

The study is worth more than >$500k over 4 years

Lammert Albers, Chief Commercial Officer of IXICO, commented: " IXICO is delighted to be awarded the contract for this MSA clinical trial reflecting IXICO's expertise in rare neurological indications. MSA is a rare neurodegenerative disorder afflicting up to 17,000 individuals in the U.S. and an estimated 23,000 in the EU. New cases of MSA in the U.S. are estimated at 1,900 per year, and the disorder affects men and women equally ."

For further information please contact:

 
 IXICO plc                                                +44 (0)20 3763 7498 
 Giulio Cerroni, Chief Executive Officer 
  Grant Nash, Chief Financial Officer 
 
 Cenkos Securities PLC (Nominated adviser 
  and sole broker)                                        +44 (0)20 7397 8900 
 Giles Balleny / Max Gould (Corporate 
  Finance) 
 Michael F Johnson / Russell Kerr 
  (Sales 
 
 Walbrook PR Ltd                                          +44 (0)20 7933 8780 
 Paul McManus / Lianne Cawthorne                         IXICO@walbrookpr.com 
  / 
 Alice Woodings

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.

   More information is available on www.IXICO.com   and follow us on Twitter @IXICOnews

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

CNTEAPNXEDLFEFA

(END) Dow Jones Newswires

September 08, 2021 02:00 ET (06:00 GMT)

Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Ixico.
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Ixico.